The company won the ‘Service & Solution’ category of the prestigious International Innovation Award (IIA) 2021 with the "Medidata Decentralized Clinical Trial (DCT) Program"
Medidata, a Dassault Systèmes company, the global leader in creating end-to-end solutions that support the entire clinical trial process, has received the International Innovation Award (IIA) 2021 for its Decentralized Clinical Trial (DCT) Program. This is the second year in a row that Medidata has won the award, after topping its category last year for the industry’s first patient portal platform. Organized by Enterprise Asia, the annual IIA recognizes outstanding innovations in products, services and solutions, as well as organization and culture. Medidata was selected the winner of the ‘Service & Solution’ category, which saw more than 100 submissions from 10 countries.
The DCT Program by Medidata is the most comprehensive set of unified, secure technologies that enable full decentralization across the clinical trial continuum. Through the launch of the DCT Program, Medidata became the first and only company that unifies direct patient data capture technology with study oversight and monitoring, redefining end-to-end decentralization and transforming the site, sponsor, and patient experience of decentralized clinical trials.
“We are immensely proud to win the International Innovation Award two years in a row. The DCT Program is an important evolution in Medidata’s vision for how we can better serve patients and customers, by accelerating research and bringing novel therapies to market in record time. Innovations like these are crucial to our efforts in redefining end-to-end decentralization, and in enabling a patient-centric and decentralized approach to clinical research. We are therefore thrilled to receive industry recognition for an innovative approach that we believe is the future of clinical studies,” said Edwin Ng, Senior Vice President, General Manager, Asia Pacific, Medidata Solutions.
The Medidata DCT Program captures participant data remotely from anywhere, at any time. It aggregates and transforms that data, monitors the data to identify quality issues to mitigate risk and ensure patient safety, and runs powerful analytics to draw new insights leading to better outcomes for patients, researchers, sites, sponsors, and CROs. The single platform minimizes the opportunity for data discrepancies and transfer lags, which can lead to security concerns and increased risk of trial disruption. To date, Medidata has applied its decentralizing technologies across more than 44,000 clinical sites around the world in multiple languages involving more than 600,000 patients with a wide array of illnesses.
The Medidata DCT Program revolutionizes the paradigm of sponsor study oversight by supporting sponsors and CROs to easily adopt risk-based approaches to study execution, rather than historically reactionary and inefficient on-site practices. Embedded capabilities for risk identification, monitoring, and mitigation allow for truly digital oversight, where physical and virtual interaction with sites can be optimized while maintaining patient safety and data quality. The Medidata DCT Program also allows for powerful workflows driven from patient-centric data, such as shipping investigational product (IP) directly to the patient and automated dosage adjustments.
Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
For more information, contact Paul Oestreicher, external communications director at poestreicher@medidata.com.